OT-58 as an Enzyme Replacement Therapy for Patients With Cystathionine Beta-Synthase Deficient Homocystinuria (CBSDH)

OT-58 as an Enzyme Replacement Therapy for Patients With Cystathionine Beta-Synthase Deficient Homocystinuria (CBSDH)

Phase 1 clinical trials of OT-58, an enzyme replacement therapy (ERT) in development for individuals with CBS deficiency (HCU), has been initiated by Orphan Technologies with sites in the United States. For more information click here.

1

0

2796

OT-58 as an Enzyme Replacement Therapy for Patients With Cystathionine Beta-Synthase Deficient Homocystinuria (CBSDH)

1

https://www.hcunetworkaustralia.org.au/ot-58-as-an-enzyme-replacement-therapy-for-patients-with-cystathionine-beta-synthase-deficient-homocystinuria-cbsdh/